Johnson & Johnson is scheduled to report third-quarter 2026 results on October 13, with consensus estimates centering on roughly $25.3 billion in revenue and adjusted EPS near $2.55–$2.85. Traders assign an 84.5% implied probability of a beat, reflecting the company’s recent pattern of outperformance—Q2 delivered $25.31 billion in sales and $2.90 adjusted EPS, both ahead of forecasts—along with continued momentum in oncology, immunology, and neuroscience franchises. Key drivers include double-digit prescription growth for Tremfya and Caplyta, accelerating uptake of newer launches such as Icotyde and Inlexzo, and MedTech expansion in electrophysiology and cardiovascular products. Full-year guidance was raised after Q2, underscoring operational strength that appears to outweigh one-time IPR&D charges expected to pressure GAAP results. The upcoming print and any accompanying commentary on launch execution or China volume-based procurement impacts remain the immediate catalysts.